Exhibit 99.1 to the first quarter of 2024, total prescriptions (TRx) increased by approximately 14% and Fanapt net product sales increased by 14%. Additionally, new patient starts, as reflected by new to brand prescriptions (NBRx), increased by nearly threefold in the same period. 1 ® 1 Key Operational Highlights – Commercial Fanapt (iloperidone) ® • Fanapt was approved in the second quarter of 2024 for the acute treatment of bipolar I disorder. Vanda initiated the commercial launch of Fanapt in this indica ...